| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
|
Am J Psychiatry
|
2005
|
2.62
|
|
2
|
Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
|
Clin Drug Investig
|
2010
|
1.60
|
|
3
|
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
|
Expert Opin Pharmacother
|
2010
|
1.42
|
|
4
|
Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.
|
Bipolar Disord
|
2009
|
1.20
|
|
5
|
Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia.
|
Schizophr Res
|
2004
|
1.11
|
|
6
|
Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
|
Clin Ther
|
2009
|
1.08
|
|
7
|
Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder.
|
Eur Neuropsychopharmacol
|
2006
|
0.87
|
|
8
|
Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial.
|
Am J Geriatr Psychiatry
|
2006
|
0.84
|
|
9
|
A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy.
|
Clin Drug Investig
|
2015
|
0.77
|
|
10
|
Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related pain.
|
Curr Med Res Opin
|
2014
|
0.75
|
|
11
|
Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders.
|
Psychopharmacology (Berl)
|
2005
|
0.75
|